Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Instagram and Podcast Intervention for Breast Cancer Awareness and Screening

31 juli 2026 uppdaterad av: Baise Bicav, Ankara University

The Effect of an Instagram- and Podcast-Based Intervention on Women's Breast Cancer Awareness, Health Beliefs, and Screening Behaviors: A Randomized Controlled Trial

Breast cancer is the most common cancer among women worldwide. This randomized controlled trial aims to evaluate the effect of an Instagram- and podcast-based intervention on women's breast cancer awareness, health beliefs, and breast cancer screening behaviors among women aged 20-39 years.

Studieöversikt

Detaljerad beskrivning

Breast cancer is the most frequently diagnosed cancer among women worldwide and remains a major public health concern. Early detection through screening is essential for reducing breast cancer-related morbidity and mortality. However, many women continue to experience barriers to screening participation, including limited awareness, insufficient knowledge, low perceived susceptibility, fear of diagnosis, and inadequate health beliefs regarding breast cancer and its screening methods.

Digital health interventions have emerged as accessible and cost-effective approaches for delivering health education and promoting preventive health behaviors. Social media platforms, particularly Instagram, are widely used by young women and offer an effective channel for disseminating health-related information. Podcasts provide an additional narrative-based educational approach that may enhance engagement, improve information retention, and support behavior change through emotionally meaningful content.

This randomized controlled trial aims to evaluate the effectiveness of an Instagram- and podcast-based intervention in improving breast cancer awareness, health beliefs, and screening behaviors among women aged 20-39 years. Participants in the intervention group will receive evidence-based educational content through Instagram posts and podcasts, while the control group will receive no intervention during the study period. Outcomes will include breast cancer awareness, health beliefs related to breast cancer screening, and screening behaviors such as breast self-examination practices.

The findings of this study are expected to provide evidence regarding the effectiveness of combined social media and podcast-based interventions as scalable, low-cost strategies for promoting breast cancer awareness and encouraging preventive screening behaviors among women.

Studietyp

Interventionell

Inskrivning (Beräknad)

180

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

  • Namn: Zehra BİCAV
  • Telefonnummer: 0 312 329 10 10

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen

Tar emot friska volontärer

Ja

Beskrivning

Inclusion Criteria:

  • Women aged 20-39 years
  • Able to read and write Turkish
  • Turkish citizens
  • Have an active Instagram account and access it at least once daily
  • No previous diagnosis of cancer
  • Willing to participate and provide informed consent

Exclusion Criteria:

  • No access to a smartphone with the Instagram application
  • Visual, hearing, or cognitive impairment that may prevent participation in the intervention

Withdrawal Criteria:

  • Failure to complete the assigned podcast sessions during the intervention period
  • Participant request to withdraw from the study at any time

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Undersökning
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Instagram Group
Participants will receive an 8-week Instagram-based breast cancer awareness intervention.
Participants will follow the "Breast Health Academy" Instagram account and receive an 8-week Instagram-based breast cancer awareness intervention. Educational breast cancer awareness and screening content will be shared as posts and stories on Mondays, Wednesdays, and Saturdays. Reminder stories encouraging breast self-examination (BSE), such as "Do not forget to perform your monthly BSE" and "Remember to perform BSE this week," will be shared on Tuesdays, Thursdays, and Sundays. Stories will also be saved as highlights. No content will be shared on Fridays, and all posts and stories will be published at the same time each day.
Experimentell: Instagram + Podcast Group
Participants will receive an 8-week Instagram- and podcast-based breast cancer awareness intervention.
Participants will follow the "Breast Health Academy Plus" Instagram account and receive an 8-week Instagram- and podcast-based breast cancer awareness intervention. Educational breast cancer awareness and screening content will be shared as posts and stories on Mondays, Wednesdays, and Saturdays. Reminder stories encouraging breast self-examination (BSE) will be shared on Tuesdays, Thursdays, and Sundays and saved as highlights. In addition, one educational podcast episode developed for the intervention will be delivered weekly via Instagram direct message every Friday. All content will be provided at the same time each day throughout the intervention period.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Breast Cancer Awareness Scale
Tidsram: Assessments will be performed at baseline and Week 8.
The Breast Cancer Awareness Measure assesses awareness of breast cancer symptoms, breast self-examination practices, and age-related risk perception. Total scores range from 0 to 3, with higher scores indicating greater breast cancer awareness.
Assessments will be performed at baseline and Week 8.
Champion's Health Belief Model Scale in Breast Cancer Screening
Tidsram: Assessments will be performed at baseline and Week 8.
The Champion's Health Belief Model Scale (CHBMS) for Breast Cancer Screening is a validated instrument used to assess health beliefs related to breast cancer screening. The Turkish version consists of six subscales: perceived susceptibility (3 items), perceived seriousness (6 items), health motivation (5 items), perceived benefits of breast self-examination (BSE) (4 items), perceived barriers to BSE (8 items), and BSE self-efficacy/confidence (10 items). Each subscale is evaluated separately, and no total score is calculated. Higher scores on the perceived susceptibility, perceived seriousness, health motivation, BSE benefits, and BSE self-efficacy/confidence subscales indicate stronger health beliefs, whereas higher scores on the BSE barriers subscale indicate greater perceived barriers to breast cancer screening and breast self-examination.
Assessments will be performed at baseline and Week 8.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Participant Satisfaction (VAS)
Tidsram: Assessed at Week 8.
Participant satisfaction with the Instagram- and podcast-based intervention will be assessed using a 0-10 Visual Analog Scale (VAS), where 0 indicates "not satisfied at all" and 10 indicates "extremely satisfied."
Assessed at Week 8.
Breast Cancer Screening Behavior Questionnaire
Tidsram: Assessments will be performed at baseline and Week 8.
Breast Cancer Screening Behavior Questionnaire. A researcher-developed 3-item questionnaire assessing breast cancer screening behaviors, including breast self-examination within the previous month, clinical breast examination by a healthcare professional, and mammography uptake or scheduling. Each item is recorded as Yes or No and analyzed separately. No total score is calculated; therefore, minimum and maximum scores are not applicable.
Assessments will be performed at baseline and Week 8.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Baise Bicav, Yuksek Ihtisas University
  • Huvudutredare: Zehra Bicav, Yuksek Ihtisas University
  • Studierektor: Sevinç Kutlutürkan, Ankara University
  • Studierektor: Filiz Ünal Toprak, Saglik Bilimleri Universitesi

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

6 juli 2026

Primärt slutförande (Beräknad)

6 oktober 2026

Avslutad studie (Beräknad)

31 december 2026

Studieregistreringsdatum

Först inskickad

23 juni 2026

Först inskickad som uppfyllde QC-kriterierna

23 juni 2026

Första postat (Faktisk)

29 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 augusti 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

31 juli 2026

Senast verifierad

1 juli 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • AU-HEM-BB-02

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera